The abstract is read at the publisher; the summary is JClub's.
In neonatal rat pups with experimental necrotizing enterocolitis, hPSC-EV therapy restored SOX9+, OLFM4+, and HOPX+ intestinal stem cell populations to near-control levels.
- Why it matters: NEC in premature infants disrupts the epithelial barrier and depletes intestinal stem cells, but how reserve stem cell subtypes change during early development—and whether they can be rescued—remains unclear.
- What they did: Neonatal rats were assigned to breastfed controls (BF), NEC, or NEC treated with hPSC-EVs (NEC-EV), then ileum was assessed at 32, 56, and 96 hours using histology and immunostaining for SOX9, OLFM4, HOPX, BMI1, and Ki67.
- The result: NEC caused early and sustained loss of SOX9+ and OLFM4+ aISC populations and reduced HOPX+ rISC abundance by blocking normal HOPX+ expansion, while hPSC-EVs improved architecture and brought these markers back near control.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.